iX Biopharma Ltd. (SG:42C)
SGX:42C
Want to see SG:42C full AI Analyst Report?
42C Stock Chart & Stats
S$0.40
>-S$0.01(-4.00%)
At close: 4:00 PM EST
S$0.40
>-S$0.01(-4.00%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.46
Previous CloseN/A
Volume104.10K
Average Volume (3M)15.11M
Market Cap
S$388.77M
Enterprise ValueS$389.73M
Total Cash (Recent Filing)S$866.00K
Total Debt (Recent Filing)S$5.90M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,050,720,000
10 Day Avg. Volume11,332,920
30 Day Avg. Volume15,113,843
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)38.32
Price to Sales (P/S)1.80
P/FCF Ratio-3.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
S$1.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary WaferiX PlatformOwning the WaferiX sublingual wafer platform provides a durable product differentiation and IP foundation that supports licensing, formulation advantage for rapid delivery, and barriers to entry. This structural asset enables recurring licensing, manufacturing and partner-led commercialization opportunities over multiple product cycles.
Partnership/licensing Business ModelA partner-focused commercialization model shifts market-entry and distribution risks to local partners, enabling scalable revenue streams (upfront, milestones, royalties) and lower direct commercialization capex. Structurally this diversifies market exposure and conserves internal resources for R&D and platform improvement.
Modest Revenue Growth And Improving Gross MarginConsistent albeit modest top-line growth and an improving gross margin indicate underlying product traction and some pricing or cost recovery on the wafer business. If sustained, higher gross margins provide room to absorb SG&A and R&D investments and can be a foundation for future operating leverage as scale increases.
Bears Say
High Financial LeverageVery high debt relative to equity materially increases financial risk and constrains strategic flexibility. Elevated leverage raises interest/service obligations, limits ability to fund development or commercialization internally, and increases vulnerability to revenue shortfalls or higher financing costs over the coming months.
Persistent Losses And Negative ROEDeep, ongoing losses and a negative return on equity reflect an inability to convert revenues into shareholder value. Over time this erodes equity, hampers reinvestment capacity, and signals structural profitability issues that require either meaningful margin improvement or external capital to sustain operations.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows indicate the business burns cash to operate and grow. Declining FCF growth reduces runway and increases dependence on debt or equity financing, which can be dilutive or costly given the high leverage, creating structural funding risk for ongoing development and commercialization.
iX Biopharma Ltd. News
42C FAQ
What was iX Biopharma Ltd.’s price range in the past 12 months?
iX Biopharma Ltd. lowest share price was S$0.01 and its highest was S$0.46 in the past 12 months.
What is iX Biopharma Ltd.’s market cap?
iX Biopharma Ltd.’s market cap is S$388.77M.
When is iX Biopharma Ltd.’s upcoming earnings report date?
iX Biopharma Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 113 days.
How were iX Biopharma Ltd.’s earnings last quarter?
iX Biopharma Ltd. released its earnings results on Feb 08, 2026. The company reported -S$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.002.
Is iX Biopharma Ltd. overvalued?
According to Wall Street analysts iX Biopharma Ltd.’s price is currently Undervalued.
Does iX Biopharma Ltd. pay dividends?
iX Biopharma Ltd. does not currently pay dividends.
What is iX Biopharma Ltd.’s EPS estimate?
iX Biopharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iX Biopharma Ltd. have?
iX Biopharma Ltd. has 1,050,720,000 shares outstanding.
What happened to iX Biopharma Ltd.’s price movement after its last earnings report?
iX Biopharma Ltd. reported an EPS of -S$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.524%.
Which hedge fund is a major shareholder of iX Biopharma Ltd.?
Currently, no hedge funds are holding shares in SG:42C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
iX Biopharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
S$1.00 (150.00% Upside)
S$1.00 (150.00% Upside)
Insider Transactions
Sold Shares
Worth S$3.6M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
434.78%
12-Months-Change
Fundamentals
Return on Equity
-450.81%
Trailing 12-Months
Asset Growth
21.42%
Trailing 12-Months
Company Description
iX Biopharma Ltd.
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, and insomnia. The company is also developing Wafermine, a racemic ketamine sublingual wafer, which has completed phase-2 clinical trial for the treatment of complex regional pain syndrome, as well as psychiatric conditions, including depression; iXB 401, a sublingual semaglutide wafer that is in pre-clinical development for the treatment of Type 2 Diabetes and Obesity; SL-NAD+, a sublingual NAD+ wafer to increase the body's NAD+ levels, energy levels, and alertness; iXB 120 that has completed Phase I clinical trial for acute agitation; IXB-214, which has completed Phase I clinical trial for complex regional pain syndrome; and IXB-314 that has completed Phase I clinical trial for treatment resistant depression. In addition, it develops BnoX that is in a phase-1 clinical trial for moderate to severe pain; NAD+ for sarcopenia; iXB 321, an influenza vaccine; iXB 322, a novel low-dose interferon sublingual wafe for respiratory viral prophylaxis; and LumeniX, a sublingual glutathione wafer for skin brightening and immunity. iX Biopharma Ltd. was incorporated in 2004 and is headquartered in Singapore.
42C Stock 12 Month Forecast
Average Price Target
S$1.00
▲(150.00% Upside)
Technical Analysis
Cordlife Group
―
Hyphens Pharma International Ltd.
―
Medtecs International Corporation Ltd.
―
Biolidics Ltd.
―
Singapore Institute of Advanced Medicine Holdings Ltd.
―
Options Prices
Currently, No data available
---